Development of energetic pharmacophore for the designing of 1,2,3,4-tetrahydropyrimidine derivatives as selective cyclooxygenase-2 inhibitors

Journal of Computer-Aided Molecular Design

Volumn 26, Issue 3, 2012, Pages 267-277

  Lokwani, Deepak ^a   Shah, Reecha ^b   Mokale, Santosh ^c   Shastry, Padma ^b   Shinde, Devanand ^a  

^a DR BABASAHEB AMBEDKAR MARATHWADA UNIVERSITY   (India)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

^c Y B CHAVAN COLLEGE OF PHARMACY   (India)

Author keywords

1,2,3,4 tetrahydropyrimidine; COX 2; Docking; E pharmacophore; Glide XP

Indexed keywords

PHARMACODYNAMICS;

1,2,3,4-TETRAHYDROPYRIMIDINE; COMPLEMENTARY FEATURES; CYCLO-OXYGENASE-2 INHIBITOR; CYCLOOXYGENASE 2; DOCKING; E-PHARMACOPHORE; GLIDE XP; PHARMACOPHORE MODELS; PHARMACOPHORES; SYNTHESISED;

SCAFFOLDS;

1 [4 (METHYLTHIO)PHENYL] 2 PHENYLETHANONE; 1,2,3,4 TETRAHYDROPYRIMIDINE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; ROFECOXIB; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENERGY TRANSFER; ENZYME ACTIVITY; ENZYME BINDING; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

EID: 84863104762     PISSN: 0920654X     EISSN: 15734951     Source Type: Journal    
DOI: 10.1007/s10822-011-9540-z     Document Type: Article

References (28)

1. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013-12017 (Pubitemid 24368594)
2. Tanabe T, Tohnai N (2002) Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68-69:95-114 (Pubitemid 35247390)
3. Sakamoto C, Soen S (2011) Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion 83:108-123
4. Lanas A (2010) A review of the gastrointestinal safety data - a gastroenterologist's perspective. Rheumatology 49:ii3-ii10
5. Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102 (Pubitemid 40365350)
6. Couzin J (2004) Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 306:384-385 (Pubitemid 39372409)
7. García Rodríguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52:1628-1636
8. Goodson NJ, Brookhart AM, Symmons DPM, Silman AJ, Solomon DH (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 8:367-372
9. Reddy LR, Corey EJ (2005) Facile air oxidation of the conjugate base of rofecoxib (VioxxTM), a possible contributor to chronic human toxicity. Tetrahedron Lett 46:927-929 (Pubitemid 40137930)
10. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: Randomized controlled trial. Lancet 364:675-684 (Pubitemid 39140623)
11. Fitzgerald GA (2004) Coxibs and cardiovascular disease. New Engl J Med 351:1709-1711
12. Li Y, Slatter JG, Zhang Z, Li Y, Doss GA, Braun MP, Stearns RA, Dean DC, Baillie TA, Tang W (2008) In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab Dispos 36:469-473 (Pubitemid 351185763)
13. Orjales A, Mosquera R, López B, Olivera R, Labeaga L, Núñez MT (2008) Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Bioorg Med Chem 16:2183-2199 (Pubitemid 351380955)
14. Mohamed MS, Awad SM, Sayed AI (2010) Synthesis of certain pyrimidine derivatives as antimicrobial agents and anti-inflammatory agents. Molecules 15:1882-1890
15. Alam O, Khan SA, Siddiqui N, Ahsan W, Verma SP, Gilani SJ (2010) Antihypertensive activity of newer 1,4-dihydro-5-pyrimidine carboxamides: Synthesis and pharmacological evaluation. Eur J Med Chem 45:5113-5119
16. Tale RH, Rodge AH, Hatnapure GD, Keche AP (2011) The novel 3,4-dihydropyrimidin-2(1H)-one urea derivatives of N-aryl urea: synthesis, anti-inflammatory, antibacterial and antifungal activity evaluation. Bioorg Med Chem Lett 21:4648-4651
17. Mokale SN, Shinde SS, Elgire RD, Sangshetti JN, Shinde DB (2010) Synthesis and anti-inflammatory activity of some 3-(4, 6-disubtituted-2-thioxo- 1,2,3,4-tetrahydropyrimidin-5-yl) propanoic acid derivatives. Bioorg Med Chem Lett 20:4424-4426
18. Bahekar SS, Shinde DB (2004) Synthesis and anti-inflammatory activity of some [4,6-(4-substituted aryl)-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-acetic acid derivatives. Bioorg Med Chem Lett 14:1733-1736 (Pubitemid 38340676)
19. Bahekar SS, Shinde DB (2003) Synthesis and anti-inflammatory activity of some (2-amino-6-(4-substituted aryl)-4-(4-substitutedphenyl)-1,6- dihydropyrimidine-5-yl)-acetic acid derivatives. Acta Pharm 53:223-229 (Pubitemid 37314583)
20. Durdagi S, Duff HJ, Noskov Su (2011) Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. J Chem Inf Model 51:463-474
21. Chopra M, Gupta R, Gupta S, Saluja D (2008) Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst. J Mol Model 14:1087-1099
22. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177-6196 (Pubitemid 44595196)
23. Salam NK, Nuti R, Sherman W (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model 49:2356-2368
24. Loving K, Salam NK, Sherman W (2009) Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 23:541-554
25. Ali AM, Saber GE, Mahfouz NM, EI-Gendy MA, Radwan AA, Hamid MA (2007) Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors. Arch Pharm Res 30:1186-1204
26. Garavito RM (1999) The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1441:278-287 (Pubitemid 29537747)
27. Charlier C, Michaux C (2003) Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem 38:645-659 (Pubitemid 36980661)
28. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8:127-134